• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 3. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzotriazoles

Recent Advances in the Study of N,N-Dimethyl-1H-benzotriazole-1-carboximidamide Monohydrochloride (CAS: 827042-23-9)

N,N-Dimethyl-1H-benzotriazole-1-carboximidamide Monohydrochloride (CAS: 827042-23-9) is a chemical compound that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug discovery and development. This research briefing aims to provide an overview of the latest findings related to this compound, including its synthesis, biological activity, and therapeutic potential.

Recent studies have focused on the synthesis and optimization of N,N-Dimethyl-1H-benzotriazole-1-carboximidamide Monohydrochloride, with particular emphasis on improving yield and purity. Advanced spectroscopic techniques, such as NMR and mass spectrometry, have been employed to characterize the compound and confirm its structural integrity. These efforts are critical for ensuring the reproducibility and scalability of the synthesis process, which is essential for further pharmacological evaluations.

In terms of biological activity, preliminary in vitro studies have demonstrated that N,N-Dimethyl-1H-benzotriazole-1-carboximidamide Monohydrochloride exhibits promising inhibitory effects against certain enzymes and receptors implicated in disease pathways. For instance, research has shown that the compound can modulate the activity of kinases involved in inflammatory and oncogenic processes. These findings suggest potential applications in the treatment of conditions such as cancer and autoimmune diseases.

Further investigations into the compound's mechanism of action have revealed its ability to interact with specific molecular targets, leading to the disruption of key signaling pathways. Molecular docking studies and computational modeling have provided insights into the binding interactions between the compound and its targets, offering a foundation for the design of more potent and selective derivatives. These computational approaches are complemented by experimental validations, ensuring the reliability of the predicted interactions.

Despite these promising results, challenges remain in translating the findings from bench to bedside. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed through comprehensive preclinical studies. Recent efforts have focused on optimizing the pharmacokinetic properties of N,N-Dimethyl-1H-benzotriazole-1-carboximidamide Monohydrochloride, with the aim of enhancing its therapeutic index and minimizing off-target effects.

In conclusion, N,N-Dimethyl-1H-benzotriazole-1-carboximidamide Monohydrochloride represents a valuable scaffold for the development of novel therapeutics. Ongoing research is expected to further elucidate its pharmacological profile and explore its potential in clinical applications. The integration of synthetic chemistry, computational biology, and experimental pharmacology will be crucial for advancing our understanding of this compound and its derivatives.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)